(Q35685617)

9 August 2017

1 reference

title

Recent developments in antibiotic treatment (English)

1 reference

9 August 2017

Andrés de Roux

1

1 reference

PubMed ID

15008596

9 August 2017

Hartmut Lode

series ordinal

2

1 reference

9 August 2017

1 December 2003

1 reference

Infectious Disease Clinics of North America

9 August 2017

1 reference

9 August 2017

17

1 reference

9 August 2017

4

1 reference

9 August 2017

739-751

1 reference

A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Problem pathogens (Pseudomonas aeruginosa and Acinetobacter).

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Ventilator-associated pneumonia. A multivariate analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Ventilator-associated pneumonia. European Task Force on ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Antimicrobial resistance in gram-positive pathogens isolated in the UK between October 1996 and January 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Current and future management of infections due to methicillin-resistant staphylococci infections: the role of quinupristin/dalfopristin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Linezolid: a review of its use in the management of serious gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Mechanisms for linezolid-induced anemia and thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Hematologic effects of linezolid: summary of clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Novel agents for the treatment of resistant Gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Linezolid to decrease length of stay in the hospital for patients with methicillin-resistant Staphylococcus aureus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Role of newer fluoroquinolones in lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Lower respiratory tract infections in the intensive care unit: consequences of antibiotic resistance for choice of antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Treatment options for vancomycin-resistant enterococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Clinical failures of linezolid and implications for the clinical microbiology laboratory

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Daptomycin disrupts membrane potential in growing Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

In vitro bactericidal activity of daptomycin against staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Glycopeptide derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

Safety and tolerability of quinupristin/dalfopristin: administration guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900073-4

7 January 2021

10.1016/S0891-5520(03)00073-4

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

15008596